## Click Chemistry and Implantable Biomaterial for Local Enhancement of Systemic Small Molecules

Jose M. Mejia Oneto MD/PhD<sup>1</sup>, Munish Gupta<sup>1</sup>, J. Kent Leach<sup>1,2</sup>, LeAnn Lindsay<sup>3</sup>, Jane Sykes<sup>3</sup>, Maksym Royzen<sup>4</sup>.

1. Department of Orthopaedic Surgery, University of California, Davis, Sacramento, CA

2. Department of Biomedical Engineering, University of California, Davis, CA

Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
Department of Chemistry, University at Albany, State University of New York, Albany, NY.

**Purpose:** This study presents a novel drug delivery platform aimed to optimize the local concentrations of systemic drugs through click chemistry and an implantable biomaterial. As a therapeutic proof of concept, we apply our discoveries to the construction of an antibiotic agent based on vancomycin. **Background**: Click chemistry technology allows two reaction partners to interact exclusively with each other and ignore other possible reagents present in nature. Our published studies have shown that the local concentration of a systemic radioprobe containing a click chemistry reagent can be increased by ten times to an area previously injected with an implantable biomaterial (alginate) modified with its click reaction partner (transcyclooctenes, TCO) (Ref. 1). Now we present a platform that does not only lead to localization but to subsequent release at the desired location (Fig. 1).




Figure 1. Hypothesis for approach Methods: We chemically synthesized the following molecules: an alginate modified with tetrazine (Tz-gel), as well as multiple agents modified with trans-cyclooctene (TCO): a releasable fluorophore (TCO-R-F), a nonreleasable flourophore (TCO-NR-F) and a releasable vancomycin (TCO-R-Vanco). Animal Model: After IACUC approval, in-vivo real-time biodistribution studies of fluorescence were carried out in nu/nu mice (n=2 per condition) by injecting either nothing or a type of alginate (control vs Tz-Gel). Then subjects received a tail-vein injection of TCO-R-F or TCO-NR-F. The negative controls were: 1. No gels with TCO-R-F (Negative control, mouse 1); 2. control alginate with TCO-R-F (Gel control, mouse 4). The two experimental groups were Tzgel and either TCO-R-F (Released protocol, mouse 2) or TCO-NR-F (Immobilized protocol, mouse 3). Fluorescence was measured with an IVIS Spectrum (Perkin Elmer, MA) and reported in radiance. Minimum Inhibitory Concentration (MIC) of Releasable Vancomycin: We mixed Vancomycin or TCO-R-Vanco with either a regular alginate gel or Tz-gel overnight. The following day luminescent methicillin sensitive Staph. aureus (MSSA, Xen 29, Perkin Elmer, MA) in broth were

added to the mixture and allowed to grow for 24 hours (n=3). Then luminescence was measured with an IVIS Spectrum (Perkin Elmer, MA) and reported in radiance. **Protocol:** Neg. control Released Immobilized Gel control




Figure 2. *in-vivo* proof of concept of platform **Results:** *Animal Model*: The *released* protocol showed the largest amount of radiance at 1hr then decreased over 5 hours. The *immobilized* protocol showed a large amount of radiance at 1 hr, 5 hr and 3 days. The gel control showed a small amount of radiance at 1hr that decreased promptly. The negative control did not show any focal radiance. *MIC of releasable vancomycin*: The MIC for vanco was 0.5 nmoles/mL (not shown), for TCO-R-vanco with Tz-gel was 2.0, for TCO-R-vanco with control alginate >4.0 (units: nmoles/mL).

Protocol		Gel Implant	Antibiotic	Concentration (nmoles/mL)		
				2	1	0.5
E	Experimental group	Tz-gel	TCO-R-Vanco	$\bigcirc$	0	
	Negative control	Alginate	TCO-R-Vanco			

Figure 3. MIC of luminescent MSSA

**Conclusions:** We present a system to chemically modify an implanted biomaterial with small molecules. This approach enables: 1. systemic small molecules to be immobilized at a pre-implanted material and then locally released through a cascade reaction in a mouse model. 2. a modified antibiotic construct that releases vancomycin and inhibits growth of luminescent bacteria (MSSA). **References:** 1. Mejia Oneto JM. Acta Biomat. 2014, doi: 10.1016/j.actbio.2014.08.019